Selective Serotonin Reuptake Inhibitor Suppression of HIV Infectivity and Replication
- 1 November 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Psychosomatic Medicine
- Vol. 72 (9), 925-932
- https://doi.org/10.1097/psy.0b013e3181f883ce
Abstract
Objective: To test the hypothesis that the selective serotonin reuptake inhibitor (SSRI) citalopram would down-regulate human immunodeficiency virus (HIV) infectivity and that the greatest effects would be seen in people with depression. Depression is a risk factor for morbidity and mortality in HIV/acquired immune deficiency syndrome. Serotonin (5-HT) neurotransmission has been implicated in the pathobiology of depression, and pharmacologic therapies for depression target this system. The 5-HT transporter and 5-HT receptors are widely distributed throughout the central nervous and immune systems. Depression has been associated with suppression of natural killer cells and CD8+ lymphocytes, key regulators of HIV infection. Methods: Ex vivo models for acute and chronic HIV infection were used to study the effects of citalopram on HIV viral infection and replication in 48 depressed and nondepressed women. For both the acute and chronic infection models, HIV reverse transcriptase activity was measured in the citalopram treatment condition and the control condition. Results: The SSRI significantly down-regulated the reverse transcriptase response in both the acute and chronic infection models. Specifically, citalopram significantly decreased the acute HIV infectivity of macrophages. Citalopram also significantly decreased HIV viral replication in the latently infected T-cell line and in the latently infected macrophage cell line. There was no difference in down-regulation by depression status. Conclusions: These studies suggest that an SSRI enhances natural killer/CD8 noncytolytic HIV suppression in HIV/acquired immune deficiency syndrome and decreases HIV viral infectivity of macrophages, ex vivo, suggesting the need for in vivo studies to determine a potential role for agents targeting serotonin in the host defense against HIV. SSRI = selective serotonin reuptake inhibitor; NK = natural killer; RT = reverse transcriptase; NKCC = natural killer cell cytotoxicity; PBMC = peripheral blood mononuclear cells; MDM = monocyte-derived macrophages; FCS = fetal calf serum; PMA = phorbol myristate acetate; ART = antiretroviral.Keywords
This publication has 82 references indexed in Scilit:
- Do Positive Psychosocial Factors Predict Disease Progression in HIV-1? A Review of the EvidencePsychosomatic Medicine, 2008
- Serotonin decreases HIV‐1 replication in primary cultures of human macrophages through 5‐HT1A receptorsBritish Journal of Pharmacology, 2008
- Selective Serotonin Reuptake Inhibitor and Substance P Antagonist Enhancement of Natural Killer Cell Innate Immunity in Human Immunodeficiency Virus/Acquired Immunodeficiency SyndromeBiological Psychiatry, 2008
- A novel form of immune signaling revealed by transmission of the inflammatory mediator serotonin between dendritic cells and T cellsBlood, 2006
- The Medical Management of DepressionThe New England Journal of Medicine, 2005
- Antidepressants Augment Natural Killer Cell Activity: In vivo and in vitroNeuropsychobiology, 1999
- Relationship of psychosocial factors to HIV disease progression1,2,3Annals of Behavioral Medicine, 1996
- Expression of a high-affinity serotonin transporter in human lymphocytesInternational Journal of Immunopharmacology, 1994
- Enhancement of human natural killer cell cytotoxicity by serotonin: Role of non-T/CD16+ NK cells, accessory monocytes, and 5-HT1A receptorsCellular Immunology, 1990
- Specific uptake of serotonin by murine macrophagesLife Sciences, 1988